Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The Prostate|October 1, 1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma modelB L Neubauer, K L Best, D F Counts, et al.The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.The Journal of Steroid Biochemistry and Molecular Biology|May 1, 1996
Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cellsM Kaefer, J E Audia, N Bruchovsky, et al.Cancer Research|September 1, 1992
Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinomaB L Neubauer, K L Best, R L Goode, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colonM J Zinda, M A Johnson, J D Paul, et al.The Journal of Biological Chemistry|May 29, 2000
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expressionJ R Graff, B W Konicek, A M McNulty, et al.Journal of Medicinal Chemistry|May 4, 2001
Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigenR M Adlington, J E Baldwin, G W Becker, et al.The Journal of Clinical Endocrinology and Metabolism|June 1, 1996
LY191704 inhibits type I steroid 5 alpha-reductase in human scalpB L Neubauer, H M Gray, C W Hanke, et al.Pageof 4